Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia
Schmidt C, Chapin D, Cianfrogna J, Corman M, Hajos M, Harms J, Hoffman W, Lebel L, McCarthy S, Nelson F, Proulx-LaFrance C, Majchrzak M, Ramirez A, Schmidt K, Seymour P, Siuciak J, Tingley F, Williams R, Verhoest P, Menniti F. Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia. Journal Of Pharmacology And Experimental Therapeutics 2008, 325: 681-690. PMID: 18287214, DOI: 10.1124/jpet.107.132910.Peer-Reviewed Original ResearchConceptsTreatment of schizophreniaPharmacological toolsPDE10A inhibitorsCyclic nucleotide phosphodiesterase 10ABasal ganglia functionNew pharmacological approachesMedium spiny neuronsNew therapeutic approachesNew pharmacological toolsInhibition of PDE10AImportant new targetSelective phosphodiesterase 10A inhibitorsCorticostriatothalamic circuitGanglia functionSpiny neuronsSystemic administrationTherapeutic approachesPharmacological approachesTherapeutic utilityPreclinical characterizationMammalian striatumPhosphodiesterase 10A inhibitorsPhosphodiesterase 10ARelated disordersPoor potency
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply